Unique ID issued by UMIN | UMIN000005281 |
---|---|
Receipt number | R000006279 |
Scientific Title | Direct Renin Inhibitor decreases central systolic blood pressure. |
Date of disclosure of the study information | 2011/03/23 |
Last modified on | 2012/09/24 08:56:16 |
Direct Renin Inhibitor decreases central systolic blood pressure.
Direct Renin Inhibitor decreases central systolic blood pressure.
Direct Renin Inhibitor decreases central systolic blood pressure.
Direct Renin Inhibitor decreases central systolic blood pressure.
Japan |
hypertensive patients
Medicine in general | Cardiology |
Others
NO
We examined the influence of a direct renin inhibitor, DRI, the influence on the central blood pressure(CBP).
Others
We divided patients who did not respond to standard-dose DRI administration into 2 groups: a group in which the dose was increased to a maximum, and a group in which standard-dose DRI was combined with diuretics, and examined the influence on the CBP.
Central blood pressure
The blood pressure, the aortic PWV, microalbuminuria, and high-sensitivity C-reactive protein (CRP) level.
Interventional
Parallel
Randomized
Open -no one is blinded
Active
2
Treatment
Medicine |
Essential hypertension who showed a systolic blood pressure of 140 mmHg or more after 12-week DRI administration at 150 mg/day. We employed the PROBE method, the subjects were assigned to receive an increased dose (300 mg) of DRI.
Essential hypertension who showed a systolic blood pressure of 140 mmHg or more after 12-week DRI administration at 150 mg/day. We employed the PROBE method, the subjects were assigned to receive a combination therapy with a diuretic, hydrochlorothiazide, at 12.5 mg.
20 | years-old | <= |
Not applicable |
Male and Female
Essential hypertension who showed a systolic blood pressure of 140 mmHg or more after 12-week DRI administration at 150 mg/day.
1) Secondary hypertension patients
2) Bilateral or unilateral renal arterial stenosis
3) Severe renal dysfunction requiring hemodialysis or peritoneal dialysis
4) Severe hepatopathy/nephropathy or heart disease that may affect the evaluation of drug safety
5) Patients who are deemed to be inappropriate by the investigator or sub-investigators
60
1st name | |
Middle name | |
Last name | Yoshiaki Kubota |
Nippon Medical School Department of Medicine
Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine
1-1-5, Sendagi, Bunkyo-ku, Tokyo Japan 113-8603
1st name | |
Middle name | |
Last name |
Nippon Medical School Department of Medicine
Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine
Nippon Medical School Department of Medicine
Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine
Nippon Medical School Department of Medicine
Division of Cardiology, Hepatology, Geriatrics and Integrated Medicine
Self funding
NO
2011 | Year | 03 | Month | 23 | Day |
Published
Completed
2010 | Year | 09 | Month | 01 | Day |
2011 | Year | 04 | Month | 01 | Day |
2011 | Year | 03 | Month | 21 | Day |
2012 | Year | 09 | Month | 24 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006279
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |